Pricing

DBV Technologies S.A. ADR (DBVT)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Daniel Tassé
Employees:
80
177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, I0, 92120
33(0)155427878
Stock Split History
DateRatio
2024-06-07 1:2
DBV Technologies S.A. engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available